The Journal of dermatological treatment最新文献

{"title":"Patient preferences for prurigo nodularis treatment: a discrete choice experiment.","authors":"Anthony Bewley, Sarina Elmariah, Pablo Arija, Katrin Jack, Marco Boeri, Rajesh Rout, Ramkumar Subramanian, Jorge Puelles","doi":"10.1080/09546634.2026.2710949","DOIUrl":"https://doi.org/10.1080/09546634.2026.2710949","url":null,"abstract":"<p><strong>Background: </strong>Characterized by severe pruritus and nodular lesions, prurigo nodularis (PN) is a chronic, inflammatory skin condition that significantly impairs quality of life. Few treatments are specifically approved for PN, and limited evidence exists on patient needs and preferences.</p><p><strong>Objective: </strong>To quantify treatment preferences among adults with moderate to severe PN.</p><p><strong>Methods: </strong>An online discrete choice experiment was administered to 150 adults in the UK (<i>N</i> = 75) and US (<i>N</i> = 75) including 7 attributes: onset of itch reduction, onset of skin lesions/nodules reduction, probability of no itch at 16 weeks, probability of skin healing at 16 weeks, adverse events, special warnings, and administration frequency. Data analysis was conducted using random parameter logit models.</p><p><strong>Results: </strong>Onset of itch reduction was the most important attribute, with a conditional relative importance (CRI: 36.91) 7.4 times greater than onset of skin lesions/nodules reduction (CRI: 5.02) and nearly twice as important as the probability of achieving skin healing (CRI: 22.05) or no itch at 16 weeks (CRI: 20.54). Attributes related to safety and administration frequency had CRIs between 6.3 and 3.9.</p><p><strong>Conclusion: </strong>Patients with PN prioritize rapid itch relief over long-term outcomes and safety considerations, underscoring the importance of incorporating patient preferences into clinical and payer decision-making.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2710949"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148703216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characteristics and outcomes of paradoxical palmoplantar pustulosis during secukinumab therapy in biologic-naïve patients with plaque psoriasis: a retrospective case series.","authors":"Qigong Si, Yi Zhang, Jing Li, Na Zhu, Ziqi Li, Hongxia Yan, Rina Wu, Xigetu He, Li Liu, Qiri Mu","doi":"10.1080/09546634.2026.2712039","DOIUrl":"https://doi.org/10.1080/09546634.2026.2712039","url":null,"abstract":"<p><strong>Background: </strong>Palmoplantar pustulosis (PPP) is an uncommon paradoxical reaction associated with biologic therapy. However, secukinumab-induced PPP remains poorly characterized, particularly in biologic-naïve patients with plaque psoriasis.</p><p><strong>Objective: </strong>To describe the clinical features, laboratory findings, management, and outcomes of biologic-naïve patients who developed PPP during secukinumab therapy.</p><p><strong>Methods: </strong>We conducted a retrospective case series of biologic-naïve adults with moderate-to-severe plaque psoriasis who developed new-onset PPP during secukinumab treatment. Clinical characteristics, laboratory findings, treatment modifications, and outcomes were reviewed.</p><p><strong>Results: </strong>Seven biologic-naïve patients were identified. PPP developed after a median of 10 weeks following secukinumab initiation. All patients developed de novo palmoplantar pustular lesions without a prior history of PPP. Peripheral neutrophilia was observed in all patients and was accompanied by significant increases in neutrophil and white blood cell counts compared with baseline, without evidence of infection. Secukinumab was discontinued in all cases. Clinical improvement occurred in six patients, and complete resolution was achieved in two patients after switching to tildrakizumab.</p><p><strong>Conclusions: </strong>PPP may occur as a paradoxical adverse event during secukinumab therapy, even in biologic-naïve patients. Early recognition and appropriate treatment modification are important for optimal management.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2712039"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148687250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy differences of biologic agents targeting different pathways in obese patients with psoriasis: a systematic review and meta-analysis.","authors":"Wenjing Zhou, Zhentao Xu, Haibo Yu, Xiwen Wang, Lixia Li, Xinyu Pan","doi":"10.1080/09546634.2026.2705161","DOIUrl":"10.1080/09546634.2026.2705161","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effect of obesity on biologic efficacy in psoriasis across different drug classes.</p><p><strong>Methods: </strong>PubMed, Embase, Web of Science, and Cochrane Library were searched from inception to March 2026. Studies reporting obesity‑stratified outcomes of biologics for psoriasis were included. Primary outcome was PASI90 (Psoriasis Area and Severity Index); secondary outcomes were PASI75 and PASI100. Random‑effects model was used to calculate pooled relative risks (RRs). Subgroup analyses and meta‑regression explored heterogeneity.</p><p><strong>Results: </strong>Twelve studies (4200 patients) were included. Obese patients had lower PASI90 response (RR = 0.64; 95% confidence interval (CI): 0.55-0.76; <i>I</i>² = 72%), but publication bias was present (Egger <i>p</i> < 0.001); after trim‑and‑fill correction, RR = 0.79 (95% CI: 0.58-1.08). This finding should therefore be interpreted with caution. Significant negative effects were seen for interleukin (IL)‑17 inhibitors (RR = 0.57) and IL‑12/23 inhibitors (RR = 0.43) in subgroup analyses, but not for tumor necrosis factor‑alpha (TNF‑α) or IL‑23 inhibitors, although the small number of studies for some classes limits the robustness of these estimates. PASI75 (RR = 0.52) and PASI100 (RR = 0.42) were also lower in obese patients. Biologic class, study design, region, mean body mass index (BMI), and obesity proportion were major sources of heterogeneity.</p><p><strong>Conclusions: </strong>Obesity may be associated with reduced response to biologics in psoriasis, although the PASI90 result was affected by publication bias and became non‑significant after correction. The impact appeared to differ by class, with significant effects for IL‑17 and IL‑12/23 inhibitors in subgroup analyses, but these findings require confirmation in larger studies. Weight status should be considered as one of multiple factors when selecting biologics, but current evidence does not support treatment selection based solely on obesity.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2705161"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148551930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Stapokibart reduces blood eosinophil counts in patients with moderate-to-severe atopic dermatitis: a post-hoc analysis from phase II and phase III clinical trials.","authors":"Yan Zhao, Furen Zhang, Bin Yang, Litao Zhang, Liming Wu, Yangfeng Ding, Jinyan Wang, Yumei Li, Qingchun Diao, Jingyi Li, Qing Sun, Xiaohong Zhu, Xiaoyong Man, Lihua Wang, Yanyan Feng, Tao Cai, Huiming Zeng, Linfeng Li, Jianyun Lu, Hong Ren, Fuqiu Li, Qianjin Lu, Xiaohua Tao, Rong Xiao, Chunlei Zhang, Xiujuan Xia, Hao Cheng, Chao Ji, Wenjie Zhao, Yanping Qiu, Wei Chu, Hongyue Yan, Bo Chen, Jianzhong Zhang","doi":"10.1080/09546634.2026.2670906","DOIUrl":"10.1080/09546634.2026.2670906","url":null,"abstract":"<p><strong>Background: </strong>Eosinophils are involved in the pathogenesis of atopic dermatitis (AD).</p><p><strong>Objective: </strong>This post-hoc analysis evaluated the effect of stapokibart on blood eosinophil counts in moderate-to-severe AD patients.</p><p><strong>Methods: </strong>The phase II AD002 trial (<i>n</i> = 120) randomly assigned patients to stapokibart 300 mg every 2 weeks (Q2W), 150 mg Q2W, or placebo for 16 weeks. The phase III AD005 trial (<i>n</i> = 500) randomly assigned patients to stapokibart 300 mg Q2W or placebo for 16 weeks, followed by open-label stapokibart 300 mg Q2W for 36 weeks. Efficacy and safety were analyzed in subgroups stratified by baseline blood eosinophil counts (≥500 or <500 cells/µL).</p><p><strong>Results: </strong>Stapokibart treatment resulted in sustained reductions in blood eosinophil counts versus placebo (baseline vs. Week 16: high-dose 420 vs. 235 cells/μL, low-dose 530 vs. 315 cells/μL in AD002; 370 vs. 210 cells/μL in AD005). Furthermore, stapokibart demonstrated superior efficacy over placebo in achieving higher Eczema Area and Severity Index (EASI)-75 response rates at Week 16 in both eosinophil subgroups. The incidence of adverse events was similar across eosinophil subgroups, with most events being mild or moderate.</p><p><strong>Conclusion: </strong>Stapokibart reduced blood eosinophil counts in AD patients and demonstrated favorable efficacy and safety regardless of baseline blood eosinophil counts.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2670906"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the mechanism of differential responses to combination therapy in melasma: pigmentary versus mixed pigmentary-vascular types-a clinical study based on interaction analysis.","authors":"Xiaoyan Li, Lei Nie, Wei Guo, Chen Li, Bo Sun, Dong Chen, Yajie He, Xiaotian Zhang, Yinping Zhang","doi":"10.1080/09546634.2026.2680823","DOIUrl":"10.1080/09546634.2026.2680823","url":null,"abstract":"<p><strong>Background: </strong>Melasma shows clinical heterogeneity, but the role of vascular components in treatment resistance remains unclear.</p><p><strong>Methods: </strong>This retrospective cohort study included 75 melasma patients stratified by severity (mild/moderate/severe, <i>n</i> = 25 each) and classified into pure pigmentary (M-type, <i>n</i> = 42) and mixed pigmentary-vascular (M + V-type, <i>n</i> = 33). All received low-fluence Q-switched 1064 nm laser plus oral tranexamic acid. Primary outcome was modified Melasma Area and Severity Index (mMASI) reduction. Multiple regression and interactionanalyses were performed.</p><p><strong>Results: </strong>M-type showed significantly higher mMASI reduction than M + V-type (<i>p</i> < 0.001). Treatment resistance rate was markedly higher in M + V-type (<i>p</i> < 0.001). M + V-type, diseaseduration ≥5 years, and severe disease were independent negative predictors. A significantclinical type × severity interaction was detected (<i>p</i> = 0.018), with the M + V effect most pronounced in severe patients.</p><p><strong>Conclusion: </strong>Mixed pigmentary-vascular type is independently associated with poor response, aggravated by severe disease. For severe M + V-type, adjunctive anti-vascular or anti-inflammatory strategies may be warranted.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2680823"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148214034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical response and time to improvement with 308-nm excimer laser therapy in scarring alopecia: a retrospective cohort study.","authors":"Archie Spindler, Derek Maas, Yana Boroumand, Isabella Zappi, Jerry Shapiro, Kristen I Lo Sicco","doi":"10.1080/09546634.2026.2697405","DOIUrl":"https://doi.org/10.1080/09546634.2026.2697405","url":null,"abstract":"<p><strong>Purpose: </strong>Excimer laser therapy, a 308-nm narrowband UV-B modality, has shown promise in inflammatory dermatoses, but remains understudied in scarring alopecia (SA).</p><p><strong>Materials and methods: </strong>We conducted an IRB-approved retrospective study of adults with SA treated with excimer therapy to characterize clinical outcomes, response timelines, and treatment patterns.</p><p><strong>Results: </strong>Most patients had lichen planopilaris or frontal fibrosing alopecia and received excimer as adjunctive therapy following prior multimodal treatment. Initial treatment was administered twice weekly, with a mean starting dose of 235.7mJ/cm². After a mean of 3.4 months, 60% of patients reported subjective improvement in hair or hairline appearance. Symptomatic improvements were observed in scalp pain (100%), burning (75%), and pruritus (50%), generally within two to six months. Signs of inflammation, including perifollicular hyperkeratosis and erythema, improved in 83% of affected patients. Trichoscopic measures of hair density and shaft caliber remained stable, suggesting disease stabilization without accelerated follicular loss. Adverse effects were common but mild, including erythema, burning, and pain, and did not lead to koebnerization.</p><p><strong>Conclusions: </strong>Overall, excimer therapy was well-tolerated and associated with meaningful clinical and symptomatic improvement. These findings support excimer therapy as a potentially effective adjunctive treatment for inflammatory control and stabilization in SA, with response typically occurring within the first several months of therapy.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2697405"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148393240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Application of a subcutaneous tissue pedicle flap combined with a labial mucosa flap for reconstruction of full-thickness lower lip defects: a prospective observational study.","authors":"Jianbo Chen, Zhibing Fu, Yifei Xie, Ningling Wu, Lu Zhou, Yujin Li, Meng Wu, Zeng Jinrong","doi":"10.1080/09546634.2026.2617778","DOIUrl":"10.1080/09546634.2026.2617778","url":null,"abstract":"<p><strong>Background: </strong>Reconstruction of full-thickness lower-lip defects after skin cancer excision is challenging, as both oral function and appearance must be restored. Conventional methods may be insufficient for moderate-sized defects.</p><p><strong>Materials and methods: </strong>This prospective observational study included 36 patients with T1-T2N0M0 basal or squamous cell carcinoma (SCC) of the lower lip treated between January 2021 and April 2023. Defects involving roughly one-third to two-thirds of the lip were repaired using a combined subcutaneous pedicle flap and labial mucosa flap. Patients were followed for 6-24 months. Functional and aesthetic outcomes, wound healing, scar quality, and recurrence were assessed using standardized scoring systems.</p><p><strong>Results: </strong>Delayed healing was more common in patients over 70 years (37.5% <i>vs</i>. 5.0%). Defects > 2.0 cm had lower functional scores and higher delayed healing. Moist wound care reduced delayed healing compared with dry healing (exploratory). Tumor recurrence was 10.5% for SCC and 5.8% for BCC. Overall, functional and aesthetic outcomes remained high.</p><p><strong>Conclusions: </strong>The combined flap technique is a safe, effective option for moderate-sized full-thickness lower-lip defects, providing reliable functional restoration and satisfactory cosmetic results.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2617778"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146145356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.","authors":"Jade Logger, Jan Willem Kallewaard, Robbert Visscher, Patrick Kemperman","doi":"10.1080/09546634.2026.2646556","DOIUrl":"10.1080/09546634.2026.2646556","url":null,"abstract":"<p><strong>Background: </strong>Neurocutaneous dysesthesia (ND) is characterized by abnormal skin sensations such as pruritus or burning without an underlying skin condition. It is caused by nerve damage or compression. Location and extent of symptoms vary greatly depending on the affected somatosensory site(s). Treatment is challenging and step-by-step guidelines are lacking. Local therapy offers a valuable first step, especially in mild cases or when systemic agents are contraindicated. Although numerous studies have described a variety of local treatment options for ND, no clear overview of these options existed.</p><p><strong>Aim: </strong>In this review, we provide an overview of available local treatment modalities for ND and explain their mechanisms of action.</p><p><strong>Findings: </strong>The following local treatment options are described: capsaicin, calcineurin inhibitors, menthol, pramoxine/lidocaine/prilocaine, ambroxol, phenytoin, strontium, amitriptyline, doxepin, duloxetine, baclofen, gabapentin, cannabinoids, loperamide, naltrexone, clonidine, prazosin, acetylsalicylic acid, diclofenac, aprepitant, ketamine, calamine, polidocanol, and botulinum toxin type A.</p><p><strong>Conclusions: </strong>Local therapy offers a valuable and often well-tolerated first step in managing ND. Unfortunately, high-quality evidence is scarce and treatment efficacy remains unpredictable. Clinicians are advised to start with low concentrations, discuss off-label use, and monitor for side effects. Until robust guidelines are available, a cautious trial-and-error approach remains the cornerstone of management.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2646556"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147517809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experts' view on the management of scalp seborrheic dermatitis in Italy.","authors":"Bianca Maria Piraccini, Giuseppe Micali, Elisabetta Fulgione, Stefania Guida, Giacomo Caldarola","doi":"10.1080/09546634.2026.2644012","DOIUrl":"10.1080/09546634.2026.2644012","url":null,"abstract":"<p><strong>Background: </strong>Acne vulgaris is a common skin disorder that negatively affects adolescents' quality of life. Recent evidence suggests that combining isotretinoin with desloratadine may enhance treatment outcomes.</p><p><strong>Objectives and methods: </strong>This study aimed to develop a practical algorithm for SSD management in Italy, by gathering insights from Italian dermatology experts on diagnosis, treatment and long-term management of SSD.</p><p><strong>Results: </strong>According to literature review and clinical experience, accurate diagnosis of SSD requires medical history, clinical evaluation, disease severity assessment and trichoscopy. The differentiation of SSD from psoriasis, eczema, and tinea capitis is essential to guide appropriate treatment, which should counteract the main pathogenic mechanisms underlying the disease and be tailored to the severity of clinical manifestations. Topical antifungals are the first-line treatments due to their efficacy in reducing Malassezia colonization. The use of topical anti-inflammatory agents, including corticosteroids, is useful for moderate-to-severe cases, but should be limited due to potential adverse effects. Selenium disulfide may be a useful option for both acute symptom control and long-term maintenance because of its antifungal, sebostatic, keratolytic, and microbiome-restoring properties, associated with a high degree of patient satisfaction. Systemic antifungals may be considered in refractory cases.</p><p><strong>Conclusion: </strong>This experts' view provides a structured approach to SSD management in Italy, integrating clinical experience and scientific evidence.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2644012"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147501267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of discoid lupus erythematosus with crisaborole.","authors":"Yingying Dai, Deyu Song, Hongjie Liu, Xun Feng, Xian Jiang","doi":"10.1080/09546634.2026.2638633","DOIUrl":"10.1080/09546634.2026.2638633","url":null,"abstract":"<p><strong>Purpose: </strong>Discoid lupus erythematosus (DLE) is a chronic autoimmune skin disorder that primarily affects sun-exposed areas and may lead to permanent scarring and dyspigmentation if inadequately treated. Therapeutic options for DLE remain limited, and long-term use of topical corticosteroids or calcineurin inhibitors is often constrained by adverse effects, particularly on facial skin. This report aims to describe the clinical response of facial DLE to topical crisaborole treatment.</p><p><strong>Materials and methods: </strong>We report the case of a 20-year-old woman with a 7-year history of a persistent erythematous plaque on the nose, previously misdiagnosed and refractory to multiple treatments, including systemic antimalarials and topical agents. Histopathological examination and direct immunofluorescence findings supported a diagnosis of DLE without systemic involvement. The patient was treated with topical crisaborole 2% ointment once daily in combination with hydroxychloroquine.</p><p><strong>Results: </strong>Marked clinical improvement was observed after two months of treatment. Sustained remission was maintained during a seven-month follow-up period with continued crisaborole use and dose reduction of hydroxychloroquine, without recurrence or adverse effects.</p><p><strong>Conclusions: </strong>Crisaborole, a topical phosphodiesterase-4 inhibitor approved for atopic dermatitis, may represent a well-tolerated nonsteroidal therapeutic option for facial DLE, particularly in patients who are unresponsive to or intolerant of conventional treatments. Further studies are needed to clarify its efficacy and long-term safety in DLE.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"37 1","pages":"2638633"},"PeriodicalIF":3.9,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147438547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}